ORMP
ORAMED PHARMACEUTICALS INC.CIK 0001176309
Showing the last 10 days.Sign up free for 90 days
Insider trades
View all ORMP insider trades| Type | Insider | Shares | Price | Value | Traded | Filed |
|---|---|---|---|---|---|---|
| Grant | Reznick Yehuda Director | 75,670 | — | Nov 12, 2026 | Nov 14, 2026 | |
| Grant | Shapiro Benjamin Director | 73,830 | — | Nov 12, 2026 | Nov 14, 2026 | |
| Grant | Mayer Arie Director | 74,250 | — | Nov 12, 2026 | Nov 14, 2026 | |
| Grant | Aghion Daniel Director | 75,670 | — | Nov 12, 2026 | Nov 14, 2026 | |
| Grant | Kidron Nadav President and CEO, Director | 1,317,000 | — | Nov 12, 2026 | Nov 14, 2026 | |
| Grant | Hexter Joshua COO & CBO | 599,000 | — | Nov 12, 2026 | Nov 14, 2026 |
Activist & passive stakes
View all ORMP stake filings- PassiveAmendment 2Nov 13, 2026Oramed Pharmaceuticals Inc.Aquamarine Financial (Cayman) Ltd6.38% · 2,653,567 shSEC
| Filing | Holder | % Owned | Shares | Filed | SEC filing |
|---|---|---|---|---|---|
PassiveAmendment 2 | Aquamarine Financial (Cayman) Ltd in Oramed Pharmaceuticals Inc. | 6.38% | 2,653,567 | Nov 13, 2026 | SEC |
Earnings
PaidCompany revenue, EPS, net income, and guidance the moment they file, parsed from SEC 8-K earnings releases. Create a free account to get started, then unlock earnings on a paid plan.
- Revenue and adjusted / GAAP EPS per quarter
- GAAP net income with profit and loss at a glance
- Forward EPS guidance when companies provide it